Drug Topics June 18, 2024
Killian Meara

Sam Clark, MD, PhD, founder and CEO of Terran Biosciences, discusses what the future looks like for psychedelic treatments.

The FDA’s Psychopharmacologic Drugs Advisory Committee voted against the use of MDMA to treat PTSD earlier this month, giving proponents of psychedelic treatments a disappointing setback. The panel, which raised various concerns about a new drug application from Lykos Therapeutics, was the first to review a psychedelic-assisted therapy in the United States. The panel’s decision has left many wondering what the future of psychedelic medicine now looks like.

Drug Topics sat down with Sam Clark, MD, PhD, founder and CEO of Terran Biosciences, to discuss how the FDA advisory panel’s decision could impact the future of psychedelic medicine, if the decision...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Interview / Q&A, Mental Health, Pharma, Pharma / Biotech, Provider, Trends
Related Articles:
‘He needs to do much more’: RFK Jr.'s measles response under scrutiny
Marty Makary, Who Made His Name Bashing the Medical Establishment, May Soon Lead FDA
Gutting FDA Won't Make America Healthy
Google’s Pixel Watch 3 Loss of Pulse Detection Feature Receives FDA Clearance
FDA Annual Flu Vaccine Meeting and CDC’s ‘Wild to Mild’ Campaign Canceled

Share This Article